Article
Author(s):
Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80.
Medication Pearl of the Day: Durvalumab (Imfinzi)
Indication: Imfinzi is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of adult patients with unresectable, stage III non-small cell lung cancer (NSCLC).
Insight:
Sources:
Imfinzi Full Prescribing Information (den8dhaj6zs0e.cloudfront.net)
Rapid-Acting Insulin Biosimilar Receives FDA Approval for Diabetes